About 1 month ago, FDA published an interesting new policy here on evaluating a novel safety signal.
It has a lot of procedural steps but the tables are interesting.
Some examples are
and here
It will be interesting if (hydroxychloroquine and Azithromycin) will ever be a subject to NISS.